Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and TACE in advanced hepatocellular carcinoma
NCT04297280Phase 2Completed
- Sponsor
- Fudan University
- Start
- Apr 2020
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in hepatocellular carcinoma (HCC), sponsored by Fudan University. Started Apr 2020; status: completed.
02
Drugs
sintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04297280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04297280.